Search - tctmd.com

Displaying 1 - 20 of 42

Sort: Relevancy | Date

Top News in Clinical Cardiology: 2018

News Features

Top News in Clinical Cardiology: 2018

Yael L. Maxwell

December 28, 2018

Rising CVD Threatens Middle East and North Africa

News Conference News WCC 2018

Rising CVD Threatens Middle East and North Africa

December 13, 2018

Man’s Best Friend, Especially After an MI or Stroke

News Conference News WCC 2018

Man’s Best Friend, Especially After an MI or Stroke

December 11, 2018

Angina Without Obstructive Stenosis: No Longer a ‘Black Box’ Mystery, Say Experts

News Daily News

Angina Without Obstructive Stenosis: No Longer a ‘Black Box’ Mystery, Say Experts

Michael O'Riordan

November 23, 2018

Staged PCI or Complete Revasc? Physicians’ Practice Patterns Dictate Procedures

News Daily News

Staged PCI or Complete Revasc? Physicians’ Practice Patterns Dictate Procedures

Michael O'Riordan

November 20, 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors

News Conference News AHA 2018

DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors

November 10, 2018

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

News Daily News

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Michael O'Riordan

November 07, 2018

Long-term Risk Factor Control Linked to Survival in COURAGE Substudy

News Daily News

Long-term Risk Factor Control Linked to Survival in COURAGE Substudy

Yael L. Maxwell

October 30, 2018

Health Forecast for 2040: Improved Life Expectancy for Most, but Troubling Trends Ahead

News Daily News

Health Forecast for 2040: Improved Life Expectancy for Most, but Troubling Trends Ahead

October 24, 2018

Dapagliflozin Gets Partial Win in DECLARE-TIMI 58

News Daily News

Dapagliflozin Gets Partial Win in DECLARE-TIMI 58

October 02, 2018

Tafamidis, a Transthyretin Stabilizer, Offers Hope for Rare Cardiomyopathy

News Conference News ESC 2018

Tafamidis, a Transthyretin Stabilizer, Offers Hope for Rare Cardiomyopathy

Michael O'Riordan

August 27, 2018

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

News Conference News ESC 2018

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

Michael O'Riordan

August 26, 2018

Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE

News Conference News ESC 2018

Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE

August 26, 2018

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

News Conference News ESC 2018

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

August 26, 2018

BMI, Blood Pressure Strongly Linked Across Diverse Subgroups in China

News Daily News

BMI, Blood Pressure Strongly Linked Across Diverse Subgroups in China

August 21, 2018

NSAIDs Account for Large Part of Osteoarthritis-CVD Link, Study Suggests

News Daily News

NSAIDs Account for Large Part of Osteoarthritis-CVD Link, Study Suggests

June 21, 2018

Liability Reform Changes How Docs Manage Suspected Coronary Artery Disease

News Daily News

Liability Reform Changes How Docs Manage Suspected Coronary Artery Disease

Michael O'Riordan

June 07, 2018

New ORBITA Insights: Invasive Physiology Tests Track Closely With Ischemia, but Not Symptom Improvement

News Conference News EuroPCR 2018

New ORBITA Insights: Invasive Physiology Tests Track Closely With Ischemia, but Not Symptom Improvement

May 22, 2018

No Post-MI Arrhythmia Danger From Using Marijuana, Study Suggests

News Conference News HRS 2018

No Post-MI Arrhythmia Danger From Using Marijuana, Study Suggests

May 15, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.